Heart energy metabolism impairment in Western-diet induced obese mice

Neves, Fabiana Alves; Cortez, Erika; Bernardo, Amélia Faustino; Mattos, Ana Barbosa Marcondes de; Vieira, Anatalia Kutianski Gonzalez; Malafaia, Tayanne; Thole, Alessandra Alves; Rodrigues-Cunha, Alessandra Cordeiro de Souza; Garcia-Souza, Érica Patrícia; Sichieri, Rosely; Moura, Aníbal Sanchez

doi:10.1016/j.jnutbio.2013.08.014

Cited by 32 publications

(29 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results showed that PGC1-α and CPT1 levels were decreased in the I/R hearts of obese insulin-resistant rats. Although previous studies demonstrated the reduction in myocardial PGC1-α and CPT-1 protein expression in genetic obesity model (Young et al 2002) and HFD-induced obese models (Neves et al 2014, Tanajak et al 2016, the alteration in cardiac PGC1-α protein expression and cardiac mitochondrial CPT-1 protein expression in HFD-induced obese insulin-resistant with myocardial I/R injury model compared with lean model has never been reported. This study is the first to demonstrate these impairments.…”

Section: Discussionmentioning

confidence: 89%

Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury

Tanajak

Sa‐nguanmoo

Sivasinprasasn

et al. 2018

Journal of Endocrinology

View full text Add to dashboard Cite

Sodium-glucose cotransporter 2 inhibitor (SGLT2-i) effects on cardiac ischemia/reperfusion (I/R) injury are unclear. Unlike SGLT2-i, dipeptidyl peptidase 4 inhibitors (DPP4-i) have shown effective cardioprotection in cardiac I/R injury. We aimed to investigate whether SGLT2-i reduces myocardial dysfunction and myocardial injury to a greater extent than DPP4-i in obese insulin-resistant rats with/without cardiac I/R injury. The high-fat (HF) diet-induced obese insulin-resistant rats were divided into 4 groups and received the following treatments for 28 days: vehicle (HFV); vildagliptin at a dosage of 3 mg/kg/day (HFVil); dapagliflozin at a dosage of 1 mg/kg/day (HFDa) and combination drugs (HFDaVil). At the end, I/R injury was induced by a 30-min left anterior descending coronary occlusion and 120-min reperfusion. Dapagliflozin showed a greater efficacy than vildagliptin in improving the metabolic impairments, low frequency/high frequency (LF/HF) ratio, systolic blood pressure and left ventricular (LV) function in comparison to HFV rats. In cardiac I/R injury, dapagliflozin had a greater efficacy than vildagiptin in decreasing mitochondrial DRP1, cleaved caspase 3, LV dysfunction and infarct size in comparison to HFV rats. However, the combined therapy showed the greatest efficacy in attenuating LV dysfunction, mitochondrial DRP1 and infarct size in comparison to HFV rats. In conclusion, dapagliflozin has a more pronounced effect than vildagliptin in obese insulin-resistant rats for the improvement of LV function. In rats with cardiac I/R injury, although dapagliflozin had a greater efficacy on cardioprotection than vildagliptin, the combined therapy exerted the highest cardioprotective effects potentially by reducing mitochondrial fission.

show abstract

Section: Discussionmentioning

confidence: 89%

Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury

Tanajak

Sa‐nguanmoo

Sivasinprasasn

et al. 2018

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…, Neves et al . ). It has been shown that FAO was not altered in insulin‐resistant model (Atkinson et al .…”

Section: Discussionmentioning

confidence: 97%

“…Moreover, decreased FAO in HFD‐induced obesity model (Neves et al . ) and obese model (Young et al . ) has been demonstrated.…”

Section: Discussionmentioning

confidence: 99%

Fibroblast growth factor 21 (FGF21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity, cardiac mitochondrial redox homoeostasis and structural changes in pre‐diabetic rats

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The association between hyperleptinemia and UCP2 up‐regulation has been already documented in engineered rats overexpressing leptin as well as in models of exogenous transitory hyperleptinemia, and diet‐induced obesity . In the case of UCP3, exogenous leptin has been reported to reduce its expression in skeletal muscle, although a more recent study has reported the opposite .…”

Section: Discussionmentioning

confidence: 98%

Potential Role of Leptin in Cardiac Steatosis Induced by Highly Saturated Fat Intake during Adolescence

Plaza

Antonazzi

Blanco‐Urgoiti

et al. 2019

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Scope To identify the age‐dependent effect of diets containing elevated amounts of either saturated or unsaturated fatty acids on cardiac steatosis in mice. Methods and Results Five‐ and eight‐week‐old C57BL/6J mice cohorts are given free access to either a saturated or an unsaturated fatty‐acid‐enriched diet during 8 weeks. Body weight (BW) and food intake are monitored during this period. Cardiac lipid content, carnitine palmitoyltransferase‐I (CPT‐I) activity, and the amount of uncoupling proteins 2 and 3 (UCP2 and UCP3) are analyzed and correlated with blood leptin concentration. Leptin and PPARγ gene expression is quantified in white adipose tissue (WAT). Both diets have a similar effect on food intake, BW, and adiposity, independently of the age. Nevertheless, cardiac steatosis is specifically identified in adolescent mice consuming the saturated diet. These animals also display lower activity of cardiac CPT‐I, a down‐regulation of cardiac UCP2, together with lower concentration of plasma leptin. Accordingly, leptin gene expression is reduced in the visceral WAT. Conclusion Consumption of diets containing elevated amounts of saturated fat during adolescence and early adult life promotes cardiac steatosis in mice. An insufficient endocrine activity of WAT, in terms of leptin production, may account for such an effect.

show abstract

Heart energy metabolism impairment in Western-diet induced obese mice

Cited by 32 publications

References 49 publications

Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury

Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury

Fibroblast growth factor 21 (FGF21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity, cardiac mitochondrial redox homoeostasis and structural changes in pre‐diabetic rats

Potential Role of Leptin in Cardiac Steatosis Induced by Highly Saturated Fat Intake during Adolescence

Contact Info

Product

Resources

About